当前位置：
首页
>
产品中心 >
Functional_antibody >
Millipore/AB5112 | Anti-Parkin Antibody, a.a. 305-323/AB5112/50 µL
Millipore/AB5112 | Anti-Parkin Antibody, a.a. 305-323/AB5112/50 µL
市场价：
¥7600.00
美元价：
4560.00
产品分类：
功能性抗体
公司分类：
Functional_antibody
联系Q Q：
3392242852
电话号码：
4000-520-616
电子邮箱：
info@ebiomall.com
商品介绍
| Description | |
|---|---|
| CatalogueNumber | AB5112 |
| BrandFamily | Chemicon® |
| TradeName |
|
| Description | Anti-ParkinAntibody,a.a.305-323 |
| ProductInformation | |
|---|---|
| Format | Serum |
| Presentation | Rabbitserum.Lyophilized.Reconstitutewith50μLofsteriledistilledwater.Centrifugetoremoveinsolublematerial.Containsnopreservative. |
| StorageandShippingInformation | |
|---|---|
| StorageConditions | Maintainlyophilizedmaterialatat-20°Cto-70°Cforupto12monthsafterdateofreceipt.Afterreconstitutionmaintainat-20°Cto-70°Cinundilutedaliquotsforupto6months.Avoidrepeatedfreeze/thawcycles.Glycerol(ACSgradeorbetter)canbeadded(1:1)forgreaterstABIlity. |
| Applications | |
|---|---|
| Application | DetectParkinusingthisAnti-ParkinAntibody,a.a.305-323validatedforuseinELISA,WB,IH. |
| KeyApplications |
|
| ApplicationNotes | Immunohistochemistry:1:1000-1:2000 OnesiteELISA Westernblot:1:1000-1:2000(recognizesadoubletat44-52kDaonblotsofhumanbrain) Theimmunogenpeptideisavailable(cat#AG237)forpre-absorbtioncontrols. Optimalworkingdilutionsmustbedeterminedbytheenduser. |
| BIOLOGicalInformation | |
|---|---|
| Immunogen | A19aminoacidpeptide(RILGEEQYNRYQQYGAEEC)correspondingtoaminoacids305-323ofthehumanparkinmolecule.Aninternalpeptidesequencewaschosentoavoidthepossibilityofcrossreactivitywithubiquitin. |
| Epitope | a.a.305-323 |
| Host | Rabbit |
| Specificity | Parkin.Parkinson"sdiseaseisacommonneurodegenerativediseaseiscausedbyslowdeathofneuronsinthesubstantialnigra,abrainregionthatutilizestheneurotransmitterdopamine.Parkin,arecentlydiscoveredgeneencodingalargeprotein,maybeinvolvedinnormalandabnormalproteindegradationincells.RecentevidenceindicatesthatpointmutationsintheParkingeneappeartoberesponsIBLeforthepathogenesisofsomeformsofParkinson"sdisease. |
| SpeciesReactivity |
|
| AntibodyType | PolyclonalAntibody |
| EntrezGeneNumber | |
| EntrezGeneSummary | Theprecisefunctionofthisgeneisunknown;however,theencodedproteinisacomponentofamultiproteinE3ubiquitinligasecomplexthatmediatesthetargetingofsubstrateproteinsforproteasomaldegradation.MutationsinthisgeneareknowntocauseParkinsondiseaseandautosomalrecessivejuvenileParkinsondisease.Alternativesplicingofthisgeneproducesmultipletranscriptvariantsencodingdistinctisoforms.Additionalsplicevariantsofthisgenehavebeendescribedbutcurrentlylacktranscriptsupport. |
| GeneSymbol |
|
| UniProtNumber | |
| UniProtSummary | FUNCTION:SwissProt:O60260#FunctionswithinamultiproteinE3ubiquitinligasecomplex,catalyzingthecovalentattachmentofubiquitinmoietiesontosubstrateproteins.ThesesubstratesincludeSYT11,CCNE1,GPR37,STUB1,a22kDaO-linkedglycosylatedisoformofSNCAIPandSEPT5.Mayplayamoregeneralroleintheubiquitinproteasomalpathwaybyparticipatingintheremovaland/ordetoxificationofabnormallyfoldedordamagedprotein.LossofthisubiquitinligaseactivityappearstobethemechanismunderlyingpathogenesisofPARK2.Mayprotectneuronsagainstalphasynucleintoxicity,proteasomaldysfunction,GPR37accumulation,andkainate-inducedexcitotoxicity.Mayplayaroleincontrollingneurotransmittertraffickingatthepresynapticterminalandincalcium-dependentexocytosis.RegulatescyclinEduringneuronalapoptosis.Mayrepresentatumorsuppressorgene. SIZE:465aminoacids;51641Da SUBUNIT:FormsanE3ubiquitinligasecomplexwithUBE2L3orUBE2L6.PartofaSCF-likecomplex,consistingofPARK2,CUL1andFBXW7.InteractswithSNCAIP.BindstotheC2AandC2BdomainsofSYT11.InteractsandregulatestheturnoverofSEPT5.Partofacomplex,includingSTUB1,HSP70andGPR37.TheamountofSTUB1inthecomplexincreasesduringERstress.STUB1promotesthedissociationofHSP70fromPARK2andGPR37,thusfacilitatingPARK2-mediatedGPR37ubiquitination.HSP70transientlyassociateswithunfoldedGPR37andinhibitstheE3activityofPARK2,whereas,STUB1enhancestheE3activityofPARK2throughpromotionofdissociationofHSP70fromPARK2-GPR37complexes.InteractswithPSMD4andPACRG.InteractswithLRRK2.InteractswithRANBP2.InteractswithSUMO1butnotSUMO2,whichpromotesnuclearlocalizationandautoubiquitination. SUBCELLULARLOCATION:Cytoplasm.Note=Co-localizeswithSTY11inneutrites.Co-localizeswithSNCAIPinbrainstemLewybodies.Nucleus. TISSUESPECIFICITY:Highlyexpressedinthebrainincludingthesubstantianigra.Expressedinheart,testisandskeletalmuscle.Expressionisdown-regulatedorabsentintumorbiopsies,andabsentinthebrainofPARK2patients.Overexpressionprotectsdopamineneuronsfromkainate-mediatedapoptosis. DOMAIN:SwissProt:O60260Theubiquitin-likedomainbindsthePSMD4subunitof26Sproteasomes. PTM:Auto-ubiquitinatesinanE2-dependentmannerleADIngtoitsowndegradation.&S-nitrosylated.TheinhibitionofPARK2ubiquitinE3ligaseactivitybyS-nitrosylationcouldcontributetothedegenerativeprocessinPDbyimpairingtheubiquitinationofPARK2substrates. DISEASE:SwissProt:O60260#DefectsinPARK2areacauseofParkinsondisease(PD)[MIM:168600].PDisacomplex,multifactorialdisorderthattypicallymanifestsaftertheageof50years,althoughearly-onsetcases(before50years)areknown.PDgenerallyarisesasasporadicconditionbutisoccasionallyinheritedasasimplemendeliantrait.AlthoughsporadicandfamilialPDareverysimilar,inheritedformsofthediseaseusuallybeginatearlieragesandareassociatedwithatypicalclinicalfeatures.PDischaracterizedbybradykinesia,restingtremor,muscularrigidityandposturalinstability,aswellasbyaclinicallysignificantresponsetotreatmentwithlevodopa.ThepathologyofPDinvolvesthelossofdopaminergicneuronsinthesubstantianigraandthepresenceofLewybodies(intraneuronalaccumulationsofaggregatedproteins),insurvivingneuronsinvariousareasofthebrain.&DefectsinPARK2arethecauseofautosomalrecessiveearlyonsetParkinsondisease2(PARK2)[MIM:600116];alsoknownasearly-onsetparkinsonismwithdiurnalfluctuation(EPDF)orautosomalrecessivejuvenileParkinsondisease(PDJ).PARK2issymptomaticallydifferentinseveralaspectsfromidiopathicParkinsondisease,althoughclassicsymptomssuchasbradykinesia,rigidityandtremorarepresent.AdditionalclinicalfeaturesincludeearlyDOPA-induceddyskinesia,diurnalfluctuationofthesymptoms,sleepbenefit,dystoniaandhyper-reflexia.PARK2isusuallycharacterizedbyonsetbefore40,withameanageatonsetof23.2years.Pathologically,PARK2patientsshowlossofdopaminergicneuronsinthesubstantianigra,similartothatseeninParkinsondisease;however,Lewybodies(intraneuronalaccumulationsofaggregatedproteins)areabsent.&DefectsinPARK2maybeinvolvedinthedevelopmentand/orprogressionofovariancancer. SIMILARITY:Contains2IBR-typezincfingers.&Contains2RING-typezincfingers.&Contains1ubiquitin-likedomain. MISCELLANEOUS:Theparkinlocus(PRKN),adjacenttothe6qtelomereishyper-recombinableandlieswithinFRA6E,thethirdmostcommonfragilesiteintumortissue. |
| PhysicochemicalInformation |
|---|
| Dimensions |
|---|
| MaterialsInformation |
|---|
| MaterialsInformation |
|---|
品牌介绍
密理博(Millipore)公司成立于1954年，总部位于美国麻省，在全世界设有47个办事处，为100多个国家提供产品和技术服务。目前全球雇员超过5800人，在美国、法国和日本等国家拥有7家大型生产工厂，主要生产过滤膜及膜过滤产品。20世纪80年代，密理博公司进入中国市场。先后在香港、北京、上海、广州及成都设立了办事机构，并于2000年4月在上海浦东外高桥保税区建立了密理博（上海）贸易有限公司。为了更好地满足中国用户的需求，密理博中国主页于2006年11月向广大用户开放，介绍密理博中国有限公司的最新动态，力求为用户打造专业的产品与服务信息交流平台。
联络我们
